Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Augusta University Research

Neither a doctor nor a teaching hospital

Research payments

$418,132

159 payments

Through program year 2025, Augusta University Research is reported as receiving $418,132 in research payments, across 159 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $55,941 14
2024 Research $8,951 1
2023 Research $49,993 17
2022 Research $43,640 12
2021 Research $20,770 11
2020 Research $85,963 40
2019 Research $152,874 64

Breakdown

Who paid Research payments · program years 2019–2025
  1. Gilead Sciences, Inc. $223,375 88 payments
  2. Argenx US, Inc. $75,723 22 payments
  3. Pfizer Inc. $43,057 14 payments
  4. ViiV Healthcare Company $30,540 16 payments
  5. AbbVie, Inc. $26,738 2 payments
  6. Nevro Corp. $5,200 3 payments
  7. United Therapeutics Corporation $5,188 10 payments
  8. Merck Sharp & Dohme Corporation $3,318 1 payment
  9. Genentech, Inc. $2,727 1 payment
  10. Exelixis Inc. $1,875 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated Locallyadvanced Unresectable Or Metastatic Solid Tumors That Express Her2 $38,154 13 payments
  2. A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis (gMG) $35,228 7 payments
  3. A Study to Evaluate Safety Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) $26,738 2 payments
  4. A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis $21,988 5 payments
  5. PH 3 HIV Two-Year Non-Inferiority Compared to Standard of Care Safety/ $15,117 8 payments
  6. A Phase Iib, Multicenter, Open-Label, Rollover Study Evaluating the Ef $13,473 5 payments
  7. A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) $13,200 3 payments
  8. A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naive Adults $12,624 1 payment
  9. A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Subjects $12,301 1 payment
  10. A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV $10,690 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record